Shares of oncology drug maker Novocure spiked over 30% after the company reported that its METIS Phase 3 clinical trial met the primary endpoint in its NSCLC study. Shares of Novocure were up approximately 31% or almost $4 per share to more than $17 in pre-market on Wednesday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR: